Prognostic significance of epidermal growth factor receptor and vascular endothelial growth factor receptor in colorectal adenocarcinoma

Kim, Jung Yeon; Bae, Byung-Noe; Kwon, Ji Eun; Kim, Hyun-Jung; Park, Kyeongmee

doi:10.1111/j.1600-0463.2011.02752.x

Cited by 17 publications

(10 citation statements)

References 54 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Visual inspection also indicates that the expression of VEGFR2 within each diseased area is variable, as is the expression among all of the tumors in a single mouse. This has been shown in previous studies on VEGFR2 expression in colon cancer [42][43][44][45][46]52 and in our own histological evaluation of the colons as demonstrated in Fig. 3.…”

Section: In-vivo Labeling/ex-vivo Imagingsupporting

confidence: 60%

“…It has been shown that vascular endothelial growth factor receptor 2 (VEGFR2) is upregulated in many cancers, including colorectal, as it is important in tumor angiogenesis. [42][43][44][45][46][47] Currently, VEGFR2 is considered a predictor for clinical outcome and in some instances is used for targeted therapy with antiangiogenic drugs. 43,44,[48][49][50] For these reasons, quantum dots bioconjugated to VEGFR2 antibodies have the potential to provide contrast between normal colon and neoplastic lesions as well as a mechanism for evaluating the molecular changes of colorectal tumors in vivo.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Quantum dots targeted to vascular endothelial growth factor receptor 2 as a contrast agent for the detection of colorectal cancer

2014

View full text Add to dashboard Cite

Abstract. We successfully labeled colorectal cancer in vivo using quantum dots targeted to vascular endothelial growth factor receptor 2 (VEGFR2). Quantum dots with emission centered at 655 nm were bioconjugated to anti-VEGFR2 antibodies through streptavidin/biotin linking. The resulting QD655-VEGFR2 contrast agent was applied in vivo to the colon of azoxymethane (AOM) treated mice via lavage and allowed to incubate. The colons were then excised, cut longitudinally, opened to expose the lumen, and imaged en face using a fluorescence stereoscope. The QD655-VEGFR2 contrast agent produced a significant increase in contrast between diseased and undiseased tissues, allowing for fluorescence-based visualization of the diseased areas of the colon. Specificity was assessed by observing insignificant contrast increase when labeling colons of AOM-treated mice with quantum dots bioconjugated to isotype control antibodies, and by labeling the colons of saline-treated control mice. This contrast agent has a great potential for in vivo imaging of the colon through endoscopy.

show abstract

Section: In-vivo Labeling/ex-vivo Imagingsupporting

confidence: 60%

Section: Introductionmentioning

confidence: 99%

Quantum dots targeted to vascular endothelial growth factor receptor 2 as a contrast agent for the detection of colorectal cancer

2014

View full text Add to dashboard Cite

show abstract

“…Bim is sequestered by dynein cytoskeletal complexes when cells are attached to ECM. Cell detachment induces release of Bim from these complexes and causes its translocation to the mitochondria, where it interacts with Bcl-xL, neutralizing its prosurvival function [23, 24]. Loss of cell adhesion also causes the accumulation of cytoplasmic Bim via inhibiting its proteasomal degradation initiated by its phosphorylation through the ERK and PI3K/Akt pathways.…”

Section: Prosurvival Signals and Apoptotic Signals In Anoikis Resimentioning

confidence: 99%

“…Loss of cell adhesion also causes the accumulation of cytoplasmic Bim via inhibiting its proteasomal degradation initiated by its phosphorylation through the ERK and PI3K/Akt pathways. Activated Bim promotes Bax-Bak oligomerization within the OMM and induces intrinsic apoptosis pathway upon cell detachment [4, 24]. Bcl-2 modifying factor (BMF) is sequestered to myosin V motor complexes and, upon loss of cell attachment, is released.…”

Section: Prosurvival Signals and Apoptotic Signals In Anoikis Resimentioning

confidence: 99%

Anoikis Resistance: An Essential Prerequisite for Tumor Metastasis

Kim

Koo

Sung

et al. 2012

International Journal of Cell Biology

363

313

View full text Add to dashboard Cite

Metastasis is a multistep process including dissociation of cancer cells from primary sites, survival in the vascular system, and proliferation in distant target organs. As a barrier to metastasis, cells normally undergo an apoptotic process known as “anoikis,” a form of cell death due to loss of contact with the extracellular matrix or neighboring cells. Cancer cells acquire anoikis resistance to survive after detachment from the primary sites and travel through the circulatory and lymphatic systems to disseminate throughout the body. Because recent technological advances enable us to detect rare circulating tumor cells, which are anoikis resistant, currently, anoikis resistance becomes a hot topic in cancer research. Detailed molecular and functional analyses of anoikis resistant cells may provide insight into the biology of cancer metastasis and identify novel therapeutic targets for prevention of cancer dissemination. This paper comprehensively describes recent investigations of the molecular and cellular mechanisms underlying anoikis and anoikis resistance in relation to intrinsic and extrinsic death signaling, epithelial-mesenchymal transition, growth factor receptors, energy metabolism, reactive oxygen species, membrane microdomains, and lipid rafts.

show abstract

“…VEGF receptor (VEGFR)-2 and VEGFR-3 expression were identified as markers of poor prognosis in patients with surgically resected colorectal adenocarcinoma (97). Overexpression of VEGF was shown to be an important predictor of early postoperative relapse (98) and it was suggested that the inhibition of VEGF may promote the senescence of colorectal cancer cells (99).…”

Section: Growth Factors Cytokines and Angiogenic Factorsmentioning

confidence: 99%

Research and clinical applications of molecular biomarkers in gastrointestinal carcinoma (Review)

2013

View full text Add to dashboard Cite

Gastrointestinal (GI) carcinoma is a common malignant disease worldwide. Its development and progression is a multistage process involving a multifactorial etiology. Although the detailed mechanisms of the development of GI carcinoma remain controversial, the elucidation of its molecular biology over the last few years has resulted in a better perspective on its epidemiology, carcinogenesis and pathogenesis. More significantly, it is currently possible to use biological indicators or biomarkers in differential diagnosis, prognostic evaluation and specific clinical interventions. In this review, we aimed to describe the biomarkers of pathogenesis, invasion, metastasis and prognosis of GI carcinoma and discuss their potential clinical applications. The majority of these biomarkers, such as tumor-associated antigens, oncogenes and tumor suppressor genes, metastasis-associated genes, cell adhesion molecules, cytokines, growth factors and microRNAs, are currently broadly applicable.

show abstract

Prognostic significance of epidermal growth factor receptor and vascular endothelial growth factor receptor in colorectal adenocarcinoma

Cited by 17 publications

References 54 publications

Quantum dots targeted to vascular endothelial growth factor receptor 2 as a contrast agent for the detection of colorectal cancer

Quantum dots targeted to vascular endothelial growth factor receptor 2 as a contrast agent for the detection of colorectal cancer

Anoikis Resistance: An Essential Prerequisite for Tumor Metastasis

Research and clinical applications of molecular biomarkers in gastrointestinal carcinoma (Review)

Contact Info

Product

Resources

About